A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Mar 2017 According to a Pulmatrix media release, the company plans to initiate this study in 2017.
10 Mar 2017 According to a Pulmatrix media release, the company plans to read out the data from trial in 2017.
17 Jan 2017 According to a Pulmatrix media release, the U.S. Food & Drug Administration has designated PUR1900 as a Qualified Infectious Disease Product for the treatment of fungal infections in the lungs of cystic fibrosis patients.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com